Leishmaniasis is a global health problem with an estimated report of 2 million new cases every year and more than 1 billion people at risk of contracting this disease in endemic areas. The innate immune system plays a central role in controlling L. major infection by initiating a signaling cascade that results in production of pro-inflammatory cytokines and recruitment of both innate and adaptive immune cells. Upon infection with L. major, CXCL1 is produced locally and plays an important role in the recruitment of neutrophils to the site of infection. Herein, we report that L. major specifically targets murine CXCL1 for degradation. The degradation of CXCL1 is not dependent on host factors as L. major can directly degrade recombinant CXCL1 in a cell-free system. Using mass spectrometry, we discovered that the L. major protease cleaves at the C-terminal end of murine CXCL1. Finally, our data suggest that L. major metalloproteases are involved in the direct cleavage and degradation of CXCL1, and a synthetic peptide spanning the CXCL1 cleavage site can be used to inhibit L. major metalloprotease activity. In conclusion, our study has identified an immune evasion strategy employed by L. major to evade innate immune responses in mice, likely reservoirs in the endemic areas, and further highlights that targeting these L. major metalloproteases may be important in controlling infection within the reservoir population and transmittance of the disease.
42]. Keratinocytes [3] , neutrophils [43] and macrophages [44, 45] have all been suggested to produce CXCL1 (or IL-8 in humans) in response to Leishmania spp. infection. Several studies have shown that neutrophils infiltrate the site of Leishmania spp. infection as early as 1-hour post-infection and are important for optimal resolution of the infection [21, 46] . Given the importance of CXCL1 in modulating the early innate immune response, we reasoned that L. major targets CXCL1 to evade early host innate immune responses.
In this current study, we have identified murine CXCL1 as a highly specific substrate for L. major metalloprotease and a possible immune evasion strategy employed by this parasite to establish a successful infection within the murine host. We further report that L. major promotes proteolytic cleavage of murine CXCL1 at the C-terminal end to initiate its degradation. Finally, we have designed a synthetic peptide spanning the CXCL1 cleavage site that inhibits L. major protease activity. In conclusion, our study has uncovered a specific mechanism employed by L. major to degrade murine CXCL1 which may help the parasite to establish infection within the murine host.
Results

L. major infection abrogates LPS-induced CXCL1 production by bone marrow-derived macrophages
To investigate how L. major impacts innate immune responses elicited by macrophages, we stimulated bone marrow-derived macrophages (BMDM) with lipopolysaccharide (LPS) in the presence or absence of L. major (WHOM/IR/-173) infection following established protocol [32] . As detailed in the experimental outline (Fig 1A) , BMDM were stimulated with 20 ng/ml LPS in the presence or absence of 20 MOI L. major promastigotes for 48 hours. LPS stimulation of BMDM induced robust production of IL-6, TNF and CXCL1. Simultaneous LPS stimulation and L. major infection did not impact the production of IL-6 and TNF by BMDM whereas CXCL1 levels were significantly blunted (Fig 1A) . The reduction of CXCL1 was directly proportional to the concentration of L. major as demonstrated by L. major concentration dependent reduction in the levels of CXCL1 from LPS-stimulated BMDM (S1A Fig) . These data suggest that L. major specifically targets LPS-induced CXCL1 production by BMDM.
Previous studies have shown that L. major targets signaling pathways to evade immune responses and establish infection [[29] ]. To examine whether L. major specifically targeted CXCL1 expression and production, we designed an experiment whereby BMDM were infected with 20 MOI L. major for 6 hours, extracellular L. major were washed, then stimulated with 20 ng/ml LPS for the next 42 hours (Fig 1B) . Interestingly, L. major-infected BMDM produced equal levels of CXCL1 when compared to controls (Fig 1B) . These results show that inhibition of CXCL1 by L. major may not occur through modulation of intracellular signaling pathway that promotes CXCL1 expression and/or production by BMDM. L. major promastigotes once inside the macrophages transform into amastigotes. To this end, we tested the ability of lesional amastigotes to directly modulate rm-CXCL1 detection. Our results show that lesional L. major amastigotes prepared from L. major-infected footpads were able to inhibit rm-CXCL1 detection (S1B Fig). Altogether, these results suggest that both extracellular (promastigote) and intracellular (amastigote) forms of L. major are able to modulate CXCL1 levels.
CXCL1 detection is significantly reduced by L. major in a cell free system
Given that L. major pre-infection of BMDM prior to LPS stimulation did not affect CXCL1 production, we posited that L. major regulates secreted CXCL1 in the extracellular milieu. To this end, we used supernatants derived from LPS-stimulated BMDM as a source of CXCL1 and cultured 500 μl of these cell-free supernatants with 20 × 10 6 L. major promastigotes for 24 hours (Fig 2A) . While levels of IL-6 and TNF detected in the supernatants remained unchanged, levels of CXCL1 were significantly reduced after addition of L. major to the supernatants. The reduced levels of CXCL1 were not due to its short half-life in the culture, as the levels of CXCL1 in the cell free supernatants were stable up to 48 hours (S1C Fig). Thus, L. major directly dampens CXCL1 detection. We next examined whether the observed effect of L. major on CXCL1 detection was dependent on live parasites. To this end, we cultured supernatants from LPS-stimulated BMDM with L. major lysates (Lm lysate: generated by 3× freeze-thaw cycles of L. major) or supernatants from L. major culture (Lm sup: supernatant collected from stationary phase of L. major growth; Fig 2B) . Similar to the addition of live L. major, addition of Lm lysate or Lm sup also reduced CXCL1 in the supernatants while IL-6 and TNF remained unaffected (Fig 2B) . These results demonstrate that: first, L. major need not be alive to dampen CXCL1 detection; second, L. major lysate can dampen CXCL1 detection; and finally, L. major secreted factors dampen CXCL1 detection. Boiling Lm lysate or Lm sup for 20 minutes at 100ºC rescued CXCL1 detected in the supernatants, suggesting that the responsible L. major components are susceptible to heat treatment ( S2 Fig). Given the sensitivity to heat treatment, we propose that the CXCL1 regulating L. major components are proteinaceous.
L. major reduces recombinant murine CXCL1 (rm-CXCL1) levels in a cell free system
Macrophages secrete several hundreds of different proteins that may indirectly alter our observed effect of L. major components on CXCL1 [47] . To this end, we obtained recombinant murine CXCL1 (rm-CXCL1, Tonbo Biosciences, San Diego, CA) which was stable in culture up to 48 hours ( S3 Fig). Importantly, Lm sup addition to rm-CXCL1 dampened its detection by ELISA in a time-dependent manner, and boiling Lm sup rescued rm-CXCL1 detection (S3
Fig).
To further investigate the specificity of L. major in reducing rm-CXCL1 levels, we examined rm-CXCL2, rh-CXCL1, rh-CXCL2 and rh-CXCL8 sequence homology by CLUSTAL-W alignment and found significant homology between these recombinant proteins (Fig 3A) . Despite the significant homology, L. major failed to reduce levels of rm-CXCL2, rh-CXCL1, rh-CXCL2 or rh-CXCL8, demonstrating specific regulation of rm-CXCL1 (Fig 3B-3F) . As expected, L. major did not inhibit rm-TNF levels (Fig 3G) . While the C-terminal cleavage site of murine CXCL1 has high degree of sequence homology to murine CXCL2 and human CXCL1, CXCL2 and CXCL8; L. major fails to cleave murine CXCL2 or human CXCL1, CXCL2 and CXCL8. Several possibilities that may explain these discrepancies could be: 1) a requirement of specific sequence for Lm protease that is only present in murine CXCL1, and 2) the three-dimensional structure of murine CXCL1, specifically at the c-terminal end, is different from that of other CXCL homologs and orthologs. Given the specific nature of L. major (WHOM/IR/-170) in dampening rm-CXCL1 levels, we next determined whether this activity was specific to the WHOM/IR/-170 isolate. However, supernatant from L. major (IA0, isolated from a patient in Iowa who acquired L. major in Iraq [48] ) was also able to inhibit rm-CXCL1 detection when compared to the WHOM/IR/-170 strain (Fig 3H) . Furthermore 
L. major inactivates biological activity of CXCL1
Our data show that L. major reduced CXCL1 levels as demonstrated by ELISA (Figs 1-3) . Possible reasons why CXCL1 levels were reduced when incubated with L. major include: 1) L. major proteins bind to CXCL1, limiting the ability of anti-CXCL1 antibody in ELISA to interact with CXCL1 or 2) L. major proteases cleaves and degrades CXCL1. Considering both outcomes, it is possible that CXCL1, either masked or cleaved by L. major components, could still be biologically active. To this end, we performed a functional assay where rm-CXCL1 or rmCXCL1+Lm lysate was used to stimulate BMDM (Fig 4A) . As demonstrated previously, when rm-CXCL1 is incubated with L. major, rm-CXCL1 levels are significantly reduced (Fig 4B) . Lm lysate alone has very little stimulatory activity as demonstrated by mRNA induction of Cxcl1, Tnf and Il6 (Fig 4C-4E) . As expected, rm-CXCL1 induced modest increase of Cxcl1, Tnf and Il6 but rm-CXCL1+Lm lysate failed to induce Cxcl1, Tnf and Il6 mRNA (Fig 4C-4E) .
These results altogether demonstrate that L. major inactivates biological activity of rm-CXCL1.
L. major cleaves CXCL1 at the C-terminal end to promote its degradation
To determine whether CXCL1 is degraded by L. major, we incubated rm-CXCL1 with Lm lysate for various time periods and examined rm-CXCL1 by silver staining (Fig 5A) . Rm- CXCL1 was detected at approximately 10KDa by silver stain. Interestingly, when incubated with Lm lysate rm-CXCL1 showed two bands as early as 30 minutes after incubation, suggesting Lm lysate-mediated cleavage of rm-CXCL1 (Fig 5A and S4 Fig) . By 2 hours, only the cleaved rm-CXCL1 was observed and this cleaved band intensity decreased over time, suggesting further degradation (Fig 5A) . L. major-mediated cleavage of rm-CXCL1 was specific because similar experiments done with rm-CXCL2, rh-CXCL1 and rh-CXCL2 did not result in cleavage or degradation of these recombinant proteins (Fig 5B) .
Based on the cleavage pattern of rm-CXCL1 (less than 1KDa shift), cleavage either at the Nterminal or C-terminal end would result in a large fragment (detected by silver stain as the lower band, Fig 5A) and a smaller fragment (which could not be detected by silver stain; Fig  5C) . To identify the cleavage product and site, we processed the full-length rm-CXCL1 and Lm lysate-cleaved rm-CXCL1 bands by trypsin digestion and performed mass spectrometry to determine the sequence of the bands (S5 (Fig 5D) .
L. major metalloprotease cleaves CXCL1
L. major has several proteases that enable it to survive within a cell and establish infection [49] . Metalloproteases and cysteine, serine and aspartic proteases are the major proteases described in L. major [49] . To examine whether cleavage activity was dependent on proteases, we first treated our rm-CXCL1 + Lm sup culture with pan protease inhibitor (Roche and Sigma) (Fig  6A-6C) . Roche cOmplete protease inhibitor is a broad inhibitor of proteases including serine, cysteine and metalloproteases, and Sigma P8340 inhibitor is reported to inhibit serine, cysteine, acid proteases and aminopeptidases. However, the presence of protease inhibitors from Roche (cOmplete) or Sigma (P8340) did not inhibit Lm sup-mediated degradation of rm-CXCL1 as demonstrated by ELISA (Fig 6B and 6C and S6 Fig) . Marimastat, a broad inhibitor of matrix metalloproteases [50] , did not rescue the degradation of rm-CXCL1 by Lm sup (S6B Fig). EDTA treatment, which chelates metal ions such as Ca 2+ and Fe 3+ (and thus can inhibit certain metalloprotease), did not rescue rm-CXCL1 cleavage by Lm sup (Fig 6D and 6E) . Interestingly, 1,10-Phenanthroline, a Zn 2+ metalloprotease inhibitor [51] , rescued rm-CXCL1 degradation by Lm sup (Fig 6F and 6G) . While the addition of 1,10-Phenanthroline resulted in the upward shift of rm-CXCL1 bands in SDS-PAGE gels; importantly, no cleavage or degradation of rm-CXCL1 was observed (Fig 6G) . Several studies have shown that 1,10-Phenanthroline inhibits GP63, a Zn 2+ metalloprotease present on all Leishmania spp and is often used in biochemical assays to inhibit non-specific proteolytic activity of GP63 [52] . To determine whether GP63 was involved in specific cleavage of rm-CXCL1, we immunoprecipitated (IP) GP63 from Lm lysate using anti-GP63 antibody (Fig 6H) . Immunoblotting the GP63+ve and GP63-ve IP fractions for GP63 showed that GP63 was exclusively present in the IP+ve fraction and not present in the IP-ve fraction demonstrating successful immunoprecipitation of GP63 (Fig 6H) . More importantly, when these fractions were cultured with rm-CXCL1, the IP-ve (Lm lysate lacking GP63) but not the IP+ve (i.e. GP63) fraction degraded rm-CXCL1 suggesting a role for GP63-independent metalloprotease in the specific degradation of rm-CXCL1 (Fig 6I) .
Synthetic peptide spanning the CXCL1 cleavage site inhibits L. major proteolytic activity against rm-CXCL1
Our data suggest that L. major Zn 2+ metalloprotease specifically cleaves rm-CXCL1 after the K65 residue leaving a 7-mer amino acid sequence (MLKGVPK). To further examine the specificity of this L. major metalloprotease, we designed a blocking peptide that covered this cleavage site (i.e. the last 15 amino acid sequences of rm-CXCL1; Fig 7A) . The addition of blocking peptide was able to rescue Lm lysate-mediated degradation of rm-CXCL1 in a dose-dependent manner (Fig 7B) . The peptide sequence from the signal peptide region of rm-CXCL1 (peptide #1 and peptide #2, Fig 7A) did not inhibit Lm lysate-mediated degradation of rm-CXCL1, demonstrating the specificity of the blocking peptide (Fig 7B) . These data demonstrate that a synthetic peptide spanning the murine CXCL1 cleavage site can competitively inhibit L. major-mediated rm-CXCL1 degradation.
Discussion
CXCL1 is a potent neutrophil chemoattractant and is rapidly upregulated following Leishmania spp. infection in the skin [37] ; however, the role of CXCL1 during Leishmania spp. infection of mice in vivo has been understudied. Charmoy et al showed that mice deficient in CXCL1 have a slight increase in lesion size and reduced numbers of neutrophil infiltrates in chronic lesions, but the overall pathology remained similar between WT and Cxcl1 -/-mice [33] . However, it should be noted that the study used the L. major Seidman strain (LmSd) that causes a non-healing infection in C57BL/6 mice [33] . A recent study showed that Tlr2 -/-mice produce significantly lower levels of CXCL1 following L. major infections and develop smaller lesions suggesting a pathogenic role for CXCL1 [35] . Furthermore, injection of recombinant CXCL1 to Tlr2 -/-during L. major infection resulted in increased parasite numbers and disease pathology [35] . Thus, more thorough analyses are needed to determine the precise role of CXCL1 during L. major infection in mice and humans. Importantly, even depletion of neutrophils using anti-Gr1 neutralizing antibody does not always lead to increased parasitic burden, lesion or pathology [21] . While some studies with acute depletion of neutrophils reported worsened pathology during L. major infections, other studies have shown no role or even amelioration of disease pathology [5, [53] [54] [55] [56] [57] [58] [59] [60] [61] . Thus, mouse strain, L. major strain, route of infection and timing of CXCL1 release may all contribute to the fate of the infection and overall pathology. In line with this thought, two independent L. major strains were tested in our study, and both strains degraded CXCL1 in our experimental systems. Whether this degradation of murine CXCL1 is a specific feature of L. major or a more general feature of all Leishmania spp. will need further investigation.
Our initial observation demonstrated that L. major in culture with macrophages effectively inhibited LPS-induced CXCL1 production. Further examination showed that intracellular L. major within the macrophages did not inhibit LPS-induced CXCL1 production. These experiments suggest that L. major does not interfere with signaling pathways that promote CXCL1 production but directly regulates secreted CXCL1 in the extracellular milieu. L. major are present as metacyclic promastigotes in sandflies [62] . When infected into the mammalian host, L. major infect macrophages and resides within the vacuole where they transform into amastigotes, multiply and establish infection [63] . Because L. major-infected macrophages which contain amastigotes did not inhibit CXCL1 production, it could be posited that only the promastigote form of L. major degrades CXCL1. However, genome microarray analysis shows that the majority of genes are constitutively expressed in both L. major promastigotes and amastigotes (>90%) and therefore the major genes and virulent factors expressed by these different stages of L. major may not be different [64] . Thus, both L. major promastigotes and amastigotes may similarly cleave and degrade murine CXCL1 in an in vitro assay. In addition, infected macrophages can secrete exosomes containing L. major proteins [65, 66] , which could degrade murine CXCL1. We have consistently shown that L. major secreted microvesicles (i.e. exosomes) contain these metalloproteases that can degrade murine CXCL1. Physiologically, L. major promastigotes released during a sandfly bite may act locally to limit acute CXCL1 produced in response to the infection. Once L. major are phagocytosed and transformed into amastigotes, they are physically separated from the CXCL1 due to their location (amastigotes are in the vacuole while CXCL1 are secreted by the macrophages and are extracellular) and may only impact CXCL1 production through the L. major component laden exosomes.
Our studies suggest that a yet-unknown metalloprotease from L. major cleaves murine CXCL1. Given that 1,10-Phenanthroline (Zn 2+ chelator) but not EDTA (Ca 2+ and Fe 3+ metal ion chelator) or Marimastat (Matrix metalloprotease inhibitor) rescued L. major-mediated CXCL1 degradation, it is possible that the unknown metalloprotease is a Zn 2+ metalloprotease.
Our studies also demonstrate that the L. major metalloprotease is highly specific for murine CXCL1 in that its closest murine homolog, CXCL2, or human homologs, CXCL1, CXCL2 or CXCL8, were not degraded. We hypothesize that this particular L. major metalloprotease may have evolved to specifically evade host immune response in rodents. Given that human CXCL1 homologs are not susceptible to this metalloprotease, one can argue that our results may not have any importance from a public health standpoint, but we reason otherwise. Our results are highly relevant to public health because rodents are ubiquitous, serve as a reservoir for Leishmania spp. and we highlight a rodent-specific L. major evolution in targeting murine CXCL1 [67] . Our studies demonstrate that the murine CXCL1 is first cleaved at the C-terminal end after K65 releasing a 7aa residue. CXCL1 cleavage occurs as early as 30 minutes of incubation with L. major and by 4 hours the cleavage is complete in that only the cleaved bands are observed. Interestingly, we did not observe any accumulation of the cleaved CXCL1 band, suggesting continuous degradation of the cleaved form. While our data clearly demonstrate that the unknown L. major metalloprotease mediates cleavage of murine CXCL1, how the cleaved CXCL1 is further degraded will be the subject of future investigation. The cleaved murine CXCL1 (lacking the C-terminal 7 aa) may be highly unstable and undergo spontaneous degradation overtime. Alternatively, the cleaved murine CXCL1 may be susceptible to additional L. major proteases which promote its subsequent degradation.
Peptide#1 and peptide#2 were generated from the N-terminal region of full length murine CXCL1. Blocking peptide spanning the L. major cleavage site on murine CXCL1 were generated. Lm lysate-mediated degradation of rm-CXCL1 in the presence of (B) Activity of synthetic peptides from (A) in inhibiting L. major-mediated degradation of rm-CXCL1. (C In conclusion, we have identified an immune evasion strategy utilized by L. major that is highly specific to murine CXCL1 (Fig 7C) . Specifically, L. major-associated metalloprotease cleaved murine CXCL1 at K65 residue and released a C-terminal 7 amino acid fragment to promote its degradation. Finally, we have designed a peptide spanning the cleavage site of CXCL1 that inhibited murine CXCL1 cleavage by L. major. Our study altogether uncovered an immune evasion strategy employed by L. major that may have evolved in rodents and highlights how parasites may utilize diverse immune evasion strategy to establish infection within its diverse mammalian hosts.
Methods
Ethics statement
Experimental procedures that utilized mice were all approved by the University of Iowa Animal Care and Use Committee (Approved Animal Protocol # 7042004 -PI Dr. Prajwal Gurung) and performed in accordance to the Office of Laboratory Animal Welfare guidelines and the PHS Policy on Humane Care and Use of Laboratory Animals.
BMDM culture
BMDMs were prepared as described previously (32) 
L. major culture
L. major strains WHOM/IR/-173 [68] and IA0 [48] were grown in T-25 flasks with M199 media supplemented with 10% FBS, 5% HEPES and 1% penicillin-streptomycin at room temperature. BMDMs were infected with 20 MOI of L. major promastigotes for 48 hours. Conditioned L. major supernatant (Lm sup) was prepared after L. major reached the stable growth phase at approximately 20 × 10 6 / ml. Following centrifugation (3000×g) to pellet L. major, supernatants were collected and filtered using a 0.2μm vacuum filter to harvest Lm sup. Lm lysate was prepared by collecting the L. major pellet, washing 3 times with PBS followed by 3 freeze-thaw cycles of 7 × 10 9 L. major /ml in PBS. For the preparation of L. major exosomes, promastigotes were grown to stable phase and changed to serum-free media and incubated at room temperature overnight. Supernatant was obtained as above and then separated using a 100kDa molecular weight Amicon ultra-15 centrifugal filter (MilliporeSigma, Burlington, MA). The concentrated vesicles were washed twice with PBS by ultracentrifugation at 110,000xg at 4˚C for 1 hour (Beckman Optma MAX-XP Ultracentrifuge, rotor TLA 120.2; Beckman Coulter Inc., USA). The final pellet (exosomes) was resuspended in PBS and used in in vitro biochemistry assays.
L. major lesional amastigotes
BALB/c mice were injected with 2 x 10 6 L. major promastigotes / footpad. 4 weeks post infection when footpad lesions were visible, mice were euthanized and footpad harvested and homogenized in PBS. L. major burden in the footpad were determined by limiting dilution assay as described previously [32] . Footpad lysates were centrifuged at passed through a 70micron filter to eliminate cellular debris. These footpad lysates were used as a source of L. major amastigotes. These footpad lysates with L. major amastigotes at a concentration of 2.5 x 10 8 and 1.25 x 10 8 (determined by limiting dilution assay) were incubated with 2ng rm-CXCL1.
Electrophoresis and in vitro biochemistry
For in vitro reactions, 125ng of total recombinant protein was separated on 4-20% or 10-20% Novex WedgeWell Tris-Glycine precast gels (Thermofisher, Waltham, MA). For silver stain, the Pierce Mass Spec compatible silver stain kit was used per manufacturer's instructions (Thermofisher). Synthetic peptides were generated and purchased from Pierce Biotechnology (Thermofisher) and are composed of the following sequences: peptide#1: CAALLLLATSRLA; peptide#2: RLATGAPIAN; blocking peptide: LVQKIVQKMLKGVPK. For Western blot analysis a semi-dry transfer was completed using trans-blot turbo system (Bio-Rad, Hercules, CA) with Immobilon PVDF membrane. The membranes were blocked in 5% non-fat milk for 1 hour at room temperature. Membranes were probed with sheep polyclonal antibody Sp180 raised against L. chagasi promastigote GP63 at a concentration 1:1500 incubated overnight at 4˚C. The membranes were then probed with HRP-tagged secondary antibodies at room temperature for 1 hour and developed using Immobilon Forte Western HRP Substrate (MilliporeSigma) and imaged with an Odyssey Fc Infrared Imaging System (LI-COR Bioscience, Lincoln, NE). Immunoprecipitation was performed using Protein G Dynabeads and Leishmania GP63 monoclonal antibody clone 96-126 (Thermofisher). As instructed by the manufacturer, 50μL beads were washed in PBS with 0.02% Tween 20 and bound to 5μg antibody for at least 10 minutes. Following a wash, the antibody bound beads were incubated with Lm lysate for another 10 minutes and finally either antigen-antibody binding was negated by acidic (pH 2.8) 50mM Glycine treatment or bead bound antibody-antigen complexes were used directly for biochemistry.
Mass spectrometry
In-gel trypsin digestion: The gel was stained using a Pierce mass spec compatible silver stain kit (Thermofisher) per manufacturer directions. A procedure slightly modified than that described by Yu et al [69] was used for in-gel digestion. Briefly, the targeted protein bands from SDS-PAGE gel were manually excised, cut into 1mm 3 pieces, and washed in 100mM ammonium bicarbonate:acetonitrile (1:1, v/v) and 25mM ammonium bicarbonate /acetonitrile (1:1, v/v), respectively, to achieve complete de-staining. The gel pieces were further treated with acetonitrile (ACN), to effectively "dry" the gel segments and then reduced in 50μl of 10mM DTT at 56˚C for 60 min. Gel-trapped proteins were alkylated with 55mM chloroacetamide (CAM) for 30 min at room temperature. The gel pieces were washed with 25mM ammonium bicarbonate: acetonitrile (1:1, v/v) twice to remove excess DTT and CAM. 50μl of cold trypsin solution at 10ng/μl in 25mM ammonium bicarbonate was then added to the gel pieces and they were allowed to swell on ice for 60 min. Digestion was conducted at 37˚C for 16 h. Peptide extraction was performed three times, adding 100μL of 50% acetonitrile/0.1% formic acid for 0.5 h, combining the supernatants. The combined extracts were concentrated in a lyophilizer and rehydrated with 15μl of mobile phase A.
LC-MS/MS: Mass spectrometry data were collected using an Orbitrap Fusion Lumos mass spectrometer (Thermofisher) coupled to an Easy-nLC-120 System (Proxeon P/N LC1400). The autosampler is set to aspirate 3μl (estimated 0.3ug) of reconstituted digest and load the solution on a 2.5cm C18 trap (New Objective, P/N IT100-25H002) coupled to waste, HV or analytical column through a microcross assembly (IDEX, P/N UH-752). Peptides are desalted on the trap using 16μl mobile phase A for 4 min. The waste valve is then blocked and a gradient begins flowing at 0.4μl/min through a self-packed analytical column, 10cm in length × 75μm id. The fused silica column was tapered from 100μm ID (Polymicro) to~8μm at the tip using a Sutter P-2000 laser puller then packed with 2.7micron Halo C18 particles using a He-pressurized SS cylinder. Peptides were separated in-line with the mass spectrometer using a 70 min gradient composed of linear and static segments wherein buffer A is 0.1% formic acid and B is 95%ACN, 0.1% formic acid. The gradient begins first hold at 4% for 3 min then makes the following transitions (%B, min): (2, 0), (35, 46) , (60, 56) , (98, 62) , (98, 70) .
Tandem mass spectrometry on the Thermo Q-Exactive hf: Data acquisitions begin with a survey scan (m/z 380-1800) acquired on a Q-Exactive Orbitrap mass spectrometer (Thermofisher) at a resolution of 120,000 in the off-axis Orbitrap segment (MS1) with automatic gain control (AGC) set to 3E06 and a maximum injection time of 50 ms. MS1 scans were acquired every 3 sec during the 70-min gradient described above. The most abundant precursors were selected among 2-6 charge state ions at a 1E05 AGC and 70 ms maximum injection time. Ions were isolated with a 1.6 Th window using the multi-segment quadrupole and subjected to dynamic exclusion for 30 sec if they were targeted twice in the prior 30 sec. Selected ions were then subjected to high energy collision-induced dissociation (HCD) in the ion routing multipole (IRM). Targeted precursors were fragmented by (HCD) at 30% collision energy in the IRM. HCD fragment ions were analyzed using the Orbitrap (AGC 1.2E05, maximum injection time 110 ms, and resolution set to 30,000 at 400 Th). Both MS2 data were recorded as centroid and the MS1 survey scans were recorded in profile mode.
Proteomic searches: Initial spectral searches were performed with both Mascot version 2.6.2 (MatrixScience) and Byonic search engines (Protein Metrics ver. 2.8.2). Search databases were composed of the Uniprot KB for species 10090 (mouse) downloaded February 6, 2016 containing 58436 sequences. In either search, an equal number of decoy entries were created and searched simultaneously by reversing the original entries in the target database. Precursor mass tolerance was set to 5 ppm and fragments were searched at 10 ppm. A fixed 57 Da modification was assumed for cysteine residues while variable oxidation was allowed at methionine. A variable GG modification at lysine was set to monitor ubiquitylation and potential phosphorylation was accessed at Ser and Thr residues. The false discovery rate was maintained at 1% by tracking matches to the decoy database. Both Mascot and Byonic search results were combined and validated using Scaffold ver. 4.8.5 (Proteome Software). Protein assignments required a minimum of two peptides established at 70% probability (local FDR algorithm) and an overall 95% protein probability (assigned by Protein Prophet). Approximately 300 protein families (including common contaminants) were assigned at a total FDR to 1.2%. Proteins were annotated with GO terms from goa_uniprot_all.gaf downloaded on May 3, 2017.
Immunoassays and recombinant proteins
Cytokine ELISAs and multiplex immunoassays were performed according to manufacturer instructions. Mouse and human CXCL1 and CXCL2 as well as human IL-8 (CXCL8) were obtained from R&D Systems (Minneapolis, MN) and multiplex CXCL1, IL-6, and TNF were completed using ProcartaPlex assays (Thermofisher) which were run on the BioRad Bio-Plex (Luminex, Austin, TX). We obtained our recombinant proteins from Tonbo biosciences which included mouse CXCL1, CXCL2, and TNF as well as human CXCL1, CXCL2, and CXCL8.
PCR methods
RNA was extracted from BMDM cultures in TRIzol reagent (Thermofisher) followed by chloroform extraction and isopropanol precipitation. The extracted RNA was reverse-transcribed into cDNA by using qScript Supermix (Quanta Biosciences, Beverly, MA). Real-time quantitative PCR was performed on Eppendorf realplex EPgradient S Mastercycler (Eppendorf, Germany) using PerfeCTa SYBR Green SuperMix ROX (Quanta Biosciences) and the appropriate primers 
Statistical analysis and alignment
GraphPad Prism 8.0 software was used for data analysis and figure presentation. Data are shown as mean ± SEM. Statistical significance was determined by t tests (two-tailed and Mann-Whitney) for two groups, and one-way ANOVA (with Dunnett's or Tukey's multiple comparisons tests) for three or more groups. For the purpose of alignment presentation, sequences were obtained from the protein manufacturer or the NCBI protein database and figures were prepared using Jalview 2 [70] . 
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